First 400 million COVID-19 vaccine doses earmarked for UK and USA

21 May 2020

An update on AstraZeneca’s (LSE: AZN) COVID-19 vaccine candidate, AZD1222, reveals the firm has secured capacity to make one billion doses, with the first deliveries planned for as early as September 2020.

The firm also revealed it has received support of more than $1 billion from the US Biomedical Advanced Research and Development Authority (BARDA) to push development forward.

As a consequence, a Phase III clinical trial in the USA with 30,000 participants, and a pediatric trial, is planned for the fall.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK